Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ: REGN) and its peers.

Over the next few years, immuno-oncology companies, which harness the immune system to fight illnesses such as cancer, faces strong tailwinds from advancements in precision medicine (including the use of AI to improve hit rates) and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.

The 4 immuno-oncology stocks we track reported a stunning Q3. As a group, revenues beat analysts’ consensus estimates by 8.4%.

Thankfully, share prices of the companies have been resilient as they are up 7.3% on average since the latest earnings results.

Regeneron (NASDAQ: REGN)

Founded by scientists who wanted to build a company where science could thrive, Regeneron Pharmaceuticals (NASDAQ: REGN) develops and commercializes medicines for serious diseases, with key products treating eye conditions, allergic diseases, cancer, and other disorders.

Regeneron reported revenues of $3.75 billion, flat year on year. This print exceeded analysts’ expectations by 5.1%. Overall, it was an incredible quarter for the company with a solid beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.

"Regeneron had a solid financial quarter and made progress across our late-stage portfolio by securing new FDA approvals for Libtayo, Evkeeza, and Lynozyfic, receiving positive CHMP opinions for Libtayo and Dupixent, and sharing promising data across our oncology, obesity, allergy, and rare disease portfolios," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron.

Regeneron delivered the slowest revenue growth of the whole group. Interestingly, the stock is up 12% since reporting and currently trades at $655.

Is now the time to buy Regeneron? Access our full analysis of the earnings results here, it’s free for active Edge members.

Best Q3: Incyte (NASDAQ: INCY)

Founded in 1991 and evolving from a genomics research firm to a commercial-stage drug developer, Incyte (NASDAQ: INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics for cancer and inflammatory diseases.

Incyte reported revenues of $1.37 billion, up 20% year on year, outperforming analysts’ expectations by 8.5%. The business had an incredible quarter with a beat of analysts’ EPS estimates and an impressive beat of analysts’ revenue estimates.

The market seems happy with the results as the stock is up 15.1% since reporting. It currently trades at $107.12.

Is now the time to buy Incyte? Access our full analysis of the earnings results here, it’s free for active Edge members.

Weakest Q3: Natera (NASDAQ: NTRA)

Founded in 2003 as Gene Security Network before rebranding in 2012, Natera (NASDAQ: NTRA) develops and commercializes genetic tests for prenatal screening, cancer detection, and organ transplant monitoring using its proprietary cell-free DNA technology.

Natera reported revenues of $592.2 million, up 34.7% year on year, exceeding analysts’ expectations by 15.1%. It may have had the worst quarter among its peers, but its results were still good as it also locked in an impressive beat of analysts’ revenue estimates and full-year revenue guidance exceeding analysts’ expectations.

Interestingly, the stock is up 1.5% since the results and currently trades at $201.50.

Read our full analysis of Natera’s results here.

Exact Sciences (NASDAQ: EXAS)

With a mission to detect cancer earlier when it's more treatable, Exact Sciences (NASDAQ: EXAS) develops and markets cancer screening and diagnostic tests, including its flagship Cologuard stool-based colorectal cancer screening test.

Exact Sciences reported revenues of $850.7 million, up 20% year on year. This result topped analysts’ expectations by 5%. It was an exceptional quarter as it also put up a beat of analysts’ EPS estimates and a solid beat of analysts’ revenue estimates.

Exact Sciences had the weakest performance against analyst estimates and weakest full-year guidance update among its peers. The stock is flat since reporting and currently trades at $67.35.

Read our full, actionable report on Exact Sciences here, it’s free for active Edge members.

Market Update

In response to the Fed’s rate hikes in 2022 and 2023, inflation has been gradually trending down from its post-pandemic peak, trending closer to the Fed’s 2% target. Despite higher borrowing costs, the economy has avoided flashing recessionary signals. This is the much-desired soft landing that many investors hoped for. The recent rate cuts (0.5% in September and 0.25% in November 2024) have bolstered the stock market, making 2024 a strong year for equities. Donald Trump’s presidential win in November sparked additional market gains, sending indices to record highs in the days following his victory. However, debates continue over possible tariffs and corporate tax adjustments, raising questions about economic stability in 2025.

Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.